Efficacy of Diterpene Ginkgolides Meglumine injection in elderly patients with ischemic stroke: A post hoc analysis of a randomized controlled trial.

[1]  Yunman Li,et al.  PAF Receptor Inhibition Attenuates Neuronal Pyroptosis in Cerebral Ischemia/Reperfusion Injury , 2021, Molecular Neurobiology.

[2]  Zhenzhong Wang,et al.  Diterpene Ginkgolides Meglumine Injection inhibits apoptosis induced by optic nerve crush injury via modulating MAPKs signaling pathways in retinal ganglion cells. , 2021, Journal of ethnopharmacology.

[3]  Yilong Wang,et al.  Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke , 2021, Stroke.

[4]  B. Lapin,et al.  Clinical Symptom Profiles After Mild–Moderate Stroke , 2019, Journal of the American Heart Association.

[5]  R. Ihl,et al.  Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761® , 2019, CNS neuroscience & therapeutics.

[6]  Joshua A. Salomon,et al.  GLOBAL, REGIONAL, AND COUNTRY-SPECIFIC LIFETIME RISK OF STROKE, 1990–2016 , 2018, The New England journal of medicine.

[7]  S. Jayasinghe,et al.  Factors influencing pre-stroke and post-stroke quality of life among stroke survivors in a lower middle-income country , 2018, Neurological Sciences.

[8]  V. Feigin,et al.  Global Burden of Stroke. , 2017, Circulation research.

[9]  Pedro Montes,et al.  Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders. , 2015, CNS & neurological disorders drug targets.

[10]  N. Luo,et al.  Chinese time trade-off values for EQ-5D health states. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  M. Schubert-Zsilavecz,et al.  Ginkgo biloba Extracts: A Review of the Pharmacokinetics of the Active Ingredients , 2013, Clinical Pharmacokinetics.

[12]  Preeti Singh,et al.  Platelet-activating factor (PAF)-antagonists of natural origin. , 2013, Fitoterapia.

[13]  R. Ihl.  Gingko biloba extract EGb 761®: clinical data in dementia , 2012, International Psychogeriatrics.

[14]  S. Kiechl,et al.  Functional recovery after ischemic stroke—A matter of age , 2012, Neurology.

[15]  Irene Katzan,et al.  Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. , 2011, Stroke.

[16]  G. Schroth,et al.  Quality of Life in Stroke Survivors after Local Intra-Arterial Thrombolysis , 2008, Cerebrovascular Diseases.

[17]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[18]  E. Cristiano,et al.  Acute ischemic stroke and transient ischemic attack in the very old – risk factor profile and stroke subtype between patients older than 80 years and patients aged less than 80 years , 2007, European journal of neurology.

[19]  S. Gutnikov,et al.  Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study) , 2005, The Lancet.

[20]  Stephen Joel Coons,et al.  US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.

[21]  C. Wolfe,et al.  Older stroke patients in Europe: stroke care and determinants of outcome. , 2004, Age and ageing.

[22]  T. Olsen,et al.  Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study. , 2004, Age and Ageing.

[23]  R. D'Agostino,et al.  The influence of gender and age on disability following ischemic stroke: the Framingham study. , 2003, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[24]  V. Feigin,et al.  Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century , 2003, The Lancet Neurology.

[25]  Paul F. Smith,et al.  The CNS effects of Ginkgo biloba extracts and ginkgolide B , 2002, Progress in Neurobiology.

[26]  R. Rabin,et al.  EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.

[27]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[28]  P. Dorman,et al.  Is the EuroQol a valid measure of health-related quality of life after stroke? , 1997, Stroke.

[29]  Paul F. Smith,et al.  The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). , 1996, Journal of ethnopharmacology.

[30]  J. Kleijnen,et al.  Ginkgo biloba , 1992, The Lancet.

[31]  J. Kleijnen,et al.  Ginkgo biloba for cerebral insufficiency. , 1992, British journal of clinical pharmacology.